GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 1,078 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 1,078 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $89.44, for a total value of $96,416.32. Following the sale, the chief executive officer now owns 6,674 shares in the company, valued at approximately $596,922.56. This trade represents a 13.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The stock was sold at an average price of $96.71, for a total value of $1,021,160.89.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The stock was sold at an average price of $94.73, for a total value of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Stock Up 7.3 %

Shares of NASDAQ WGS opened at $97.44 on Thursday. The stock has a market cap of $2.73 billion, a PE ratio of -49.71 and a beta of 1.91. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 52-week low of $8.03 and a 52-week high of $115.60. The business has a 50-day moving average price of $84.59 and a 200 day moving average price of $70.97.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66. The firm had revenue of $95.64 million during the quarter, compared to analysts’ expectations of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. Equities research analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on WGS shares. The Goldman Sachs Group increased their price objective on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a report on Wednesday, February 19th. TD Cowen increased their price objective on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $72.33.

Institutional Trading of GeneDx

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in GeneDx by 18.5% during the 4th quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company’s stock worth $77,337,000 after acquiring an additional 156,768 shares during the period. Summit Partners Public Asset Management LLC lifted its position in GeneDx by 336.9% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company’s stock worth $58,073,000 after acquiring an additional 582,619 shares during the period. William Blair Investment Management LLC acquired a new stake in GeneDx during the 4th quarter worth approximately $51,496,000. Lord Abbett & CO. LLC acquired a new stake in GeneDx during the 4th quarter worth approximately $48,458,000. Finally, Fred Alger Management LLC raised its stake in shares of GeneDx by 38.5% during the 4th quarter. Fred Alger Management LLC now owns 546,054 shares of the company’s stock worth $41,970,000 after buying an additional 151,824 shares in the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.